The miR-143/-145 cluster regulates plasminogen activator inhibitor-1 in bladder cancer

British Journal of Cancer

Volumn 106, Issue 2, 2012, Pages 366-374

  Villadsen, S B ^a   Bramsen, J B ^a   Ostenfeld, M S ^b   Wiklund, E D ^a   Fristrup, N ^b   Gao, S ^a   Hansen, T B ^a   Jensen, T I ^a   Borre, M ^b   Rntoft, T F ^b   Dyrskjot L ^b   Kjems, J ^a  

^a AARHUS UNIVERSITY   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; MICRORNA; MICRORNA 143; MICRORNA 145; PLASMINOGEN ACTIVATOR INHIBITOR 1; UNCLASSIFIED DRUG;

ARTICLE; BLADDER; BLADDER BIOPSY; BLADDER CANCER; CANCER STAGING; DOWN REGULATION; GENE CLUSTER; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; UPREGULATION;

3' UNTRANSLATED REGIONS; BASE SEQUENCE; CELL LINE, TUMOR; DNA PRIMERS; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; IN SITU HYBRIDIZATION; MICRORNAS; MULTIGENE FAMILY; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGNOSIS; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 84856411875     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.520     Document Type: Article

References (58)

1. Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297
2. Becker M, Szarvas T, Wittschier M, vom Dorp F, Totsch M, Schmid KW, Rubben H, Ergun S (2010) Prognostic impact of plasminogen activator inhibitor type 1 expression in bladder cancer. Cancer 116: 4502-4512
3. Borralho PM, Kren BT, Castro RE, da Silva IB, Steer CJ, Rodrigues CM (2009) MicroRNA-143 reduces viability and increases sensitivity to 5-fluorouracil in HCT116 human colorectal cancer cells. FEBS J 276: 6689-6700
4. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254
5. Bramsen JB, Laursen MB, Nielsen AF, Hansen TB, Bus C, Langkjaer N, Babu BR, Hojland T, Abramov M, Van Aerschot A, Odadzic D, Smicius R, Haas J, Andree C, Barman J, Wenska M, Srivastava P, Zhou C, Honcharenko D, Hess S, Muller E, Bobkov GV, Mikhailov SN, Fava E, Meyer TF, Chattopadhyaya J, Zerial M, Engels JW, Herdewijn P, Wengel J, Kjems J (2009) A large-scale chemical modification screen identifies design rules to generate siRNAs with high activity, high stability and low toxicity. Nucleic Acids Res 37: 2867-2881
6. Bramsen JB, Pakula MM, Hansen TB, Bus C, Langkjaer N, Odadzic D, Smicius R, Wengel SL, Chattopadhyaya J, Engels JW, Herdewijn P, Wengel J, Kjems J (2010) A screen of chemical modifications identifies position-specific modification by UNA to most potently reduce siRNA off-target effects. Nucleic Acids Res 38: 5761-5773
7. Carbin BE, Ekman P, Gustafson H, Christensen NJ, Silfversward C, Sandstedt B (1991) Grading of human urothelial carcinoma based on nuclear atypia and mitotic frequency. II. Prognostic importance. J Urol 145: 972-975; discussion 975-6
8. Chen Y, Kelm RJ, Budd RC, Sobel BE, Schneider DJ (2004) Inhibition of apoptosis and caspase-3 in vascular smooth muscle cells by plasminogen activator inhibitor type-1. J Cell Biochem 92: 178-188
9. Chiyomaru T, Enokida H, Tatarano S, Kawahara K, Uchida Y, Nishiyama K, Fujimura L, Kikkawa N, Seki N, Nakagawa M (2010) miR-145 and miR-133a function as tumour suppressors and directly regulate FSCN1 expression in bladder cancer. Br J Cancer 102: 883-891
10. Cordes KR, Sheehy NT, White MP, Berry EC, Morton SU, Muth AN, Lee TH, Miano JM, Ivey KN, Srivastava D (2009) miR-145 and miR-143 regulate smooth muscle cell fate and plasticity. Nature 460: 705-710
11. Dyrskjot L, Ostenfeld MS, Bramsen JB, Silahtaroglu AN, Lamy P, Ramanathan R, Fristrup N, Jensen JL, Andersen CL, Zieger K, Kauppinen S, Ulhoi BP, Kjems J, Borre M, Orntoft TF (2009) Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro. Cancer Res 69: 4851-4860
12. Dyrskjot L, Zieger K, Kruhoffer M, Thykjaer T, Jensen JL, Primdahl H, Aziz N, Marcussen N, Moller K, Orntoft TF (2005) A molecular signature in superficial bladder carcinoma predicts clinical outcome. Clin Cancer Res 11: 4029-4036 (Pubitemid 40791566)
13. Egerod FL, Bartels A, Fristrup N, Borre M, Orntoft TF, Oleksiewicz MB, Brunner N, Dyrskjot L (2009) High frequency of tumor cells with nuclear Egr-1 protein expression in human bladder cancer is associated with disease progression. BMC Cancer 9: 385
14. Elia L, Quintavalle M, Zhang J, Contu R, Cossu L, Latronico MV, Peterson KL, Indolfi C, Catalucci D, Chen J, Courtneidge SA, Condorelli G (2009) The knockout of miR-143 and-145 alters smooth muscle cell maintenance and vascular homeostasis in mice: correlates with human disease. Cell Death Differ 16: 1590-1598
15. Esquela-Kerscher A, Slack FJ (2006) Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 6: 259-269
16. Esteller M (2008) Epigenetics in cancer. N Engl J Med 358: 1148-1159
17. Friedman RC, Farh KK, Burge CB, Bartel DP (2009) Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 19: 92-105
18. Fujikawa K, Matsui Y, Kobayashi T, Miura K, Oka H, Fukuzawa S, Sasaki M, Takeuchi H, Okabe T (2003) Predicting disease outcome of noninvasive transitional cell carcinoma of the urinary bladder using an artificial neural network model: results of patient follow-up for 15 years or longer. Int J Urol 10: 149-152 (Pubitemid 36470025)
19. Gao S, Skeldal S, Krogdahl A, Sorensen JA, Andreasen PA (2005) CpG methylation of the PAI-1 gene 50-flanking region is inversely correlated with PAI-1 mRNA levels in human cell lines. Thromb Haemost 94: 651-660 (Pubitemid 41300865)
20. Gotte M, Mohr C, Koo CY, Stock C, Vaske AK, Viola M, Ibrahim SA, Peddibhotla S, Teng YH, Low JY, Ebnet K, Kiesel L, Yip GW (2010) miR-145-dependent targeting of junctional adhesion molecule A and modulation of fascin expression are associated with reduced breast cancer cell motility and invasiveness. Oncogene 29: 6569-6580
21. Grimson A, Farh KK, Johnston WK, Garrett-Engele P, Lim LP, Bartel DP (2007) MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol Cell 27: 91-105 (Pubitemid 46991392)
22. Hendrickson DG, Hogan DJ, Herschlag D, Ferrell JE, Brown PO (2008) Systematic identification of mRNAs recruited to argonaute 2 by specific microRNAs and corresponding changes in transcript abundance. PLoS ONE 3: e2126
23. Hiti AL, Rideout WM, Laug WE, Jones PA (1990) Plasminogen activator regulation by transforming growth factor-beta in normal and neoplastic human urothelium. Cancer Commun 2: 123-128 (Pubitemid 20262728)
24. Iio A, Nakagawa Y, Hirata I, Naoe T, Akao Y (2010) Identification of noncoding RNAs embracing microRNA-143/145 cluster. Mol Cancer 9: 136
25. Kent OA, Chivukula RR, Mullendore M, Wentzel EA, Feldmann G, Lee KH, Liu S, Leach SD, Maitra A, Mendell JT (2010) Repression of the miR-143/145 cluster by oncogenic Ras initiates a tumor-promoting feed-forward pathway. Genes Dev 24: 2754-2759
26. Khan AA, Betel D, Miller ML, Sander C, Leslie CS, Marks DS (2009) Transfection of small RNAs globally perturbs gene regulation by endogenous microRNAs. Nat Biotechnol 27: 549-555
27. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP (1998) Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4: 844-847 (Pubitemid 28331029)
28. Kwaan HC, McMahon B (2009) The role of plasminogen-plasmin system in cancer. Cancer Treat Res 148: 43-66
29. Kwaan HC, Wang J, Svoboda K, Declerck PJ (2000) Plasminogen activator inhibitor 1 may promote tumour growth through inhibition of apoptosis. Br J Cancer 82: 1702-1708 (Pubitemid 30229582)
30. Lee HC, Chen CY, Au LC (2011) Systemic comparison of repression activity for miRNA and siRNA associated with different types of target sequences. Biochem Biophys Res Commun 411(2): 393-396
31. Lewis BP, Burge CB, Bartel DP (2005) Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120: 15-20 (Pubitemid 40094598)
32. Li G, Luna C, Qiu J, Epstein DL, Gonzalez P (2010) Modulation of inflammatory markers by miR-146a during replicative senescence in trabecular meshwork cells. Invest Ophthalmol Vis Sci 51: 2976-2985
33. Lijnen HR (2005) Pleiotropic functions of plasminogen activator inhibitor-1. J Thromb Haemost 3: 35-45 (Pubitemid 41647113)
34. Mansilla F, Birkenkamp-Demtroder K, Kruhoffer M, Sorensen FB, Andersen CL, Laiho P, Aaltonen LA, Verspaget HW, Orntoft TF (2007) Differential expression of DHHC9 in microsatellite stable and instable human colorectal cancer subgroups. Br J Cancer 96: 1896-1903 (Pubitemid 46912029)
35. McGarvey TW, Kariko K, Barnathan ES, Thomas J, Malkowicz SB (1998) The expression of urokinase-related genes in superficial and invasive transitional cell carcinoma. Int J Oncol 12: 175-180 (Pubitemid 28027244)
36. McMahon B, Kwaan HC (2008) The plasminogen activator system and cancer. Pathophysiol Haemost Thromb 36: 184-194
37. Michael MZ, O'Connor SM, van Holst Pellekaan NG, Young GP, James RJ (2003) Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res 1: 882-891 (Pubitemid 37288707)
38. Muth M, Hussein K, Jacobi C, Kreipe H, Bock O (2011) Hypoxia-induced down-regulation of microRNA-449a/b impairs control over targeted SERPINE1 (PAI-1) mRNA-a mechanism involved in SERPINE1 (PAI-1) overexpression. J Transl Med 9: 24
39. Muth M, Theophile K, Hussein K, Jacobi C, Kreipe H, Bock O (2010) Hypoxia-induced down-regulation of microRNA-449a/b impairs control over targeted SERPINE1 (PAI-1) mRNA-a mechanism involved in SERPINE1 (PAI-1) overexpression. J Transl Med 8: 33
40. Nagamine Y (2008) Transcriptional regulation of the plasminogen activator inhibitor type 1-with an emphasis on negative regulation. Thromb Haemost 100: 1007-1013
41. Noguchi S, Mori T, Hoshino Y, Maruo K, Yamada N, Kitade Y, Naoe T, Akao Y (2011) MicroRNA-143 functions as a tumor suppressor in human bladder cancer T24 cells. Cancer Lett 307(2): 211-220
42. Offersen BV, Nielsen BS, Hoyer-Hansen G, Rank F, Hamilton-Dutoit S, Overgaard J, Andreasen PA (2003) The myofibroblast is the predominant plasminogen activator inhibitor-1-expressing cell type in human breast carcinomas. Am J Pathol 163: 1887-1899 (Pubitemid 37310019)
43. Ostenfeld MS, Bramsen JB, Lamy P, Villadsen SB, Fristrup N, Sorensen KD, Ulhoi B, Borre M, Kjems J, Dyrskjot L, Orntoft TF (2010) miR-145 induces caspase-dependent and-independent cell death in urothelial cancer cell lines with targeting of an expression signature present in Ta bladder tumors. Oncogene 29: 1073-1084
44. Patel N, Tahara SM, Malik P, Kalra VK (2011) Involvement of miR-30c and miR-301a in immediate induction of plasminogen activator inhibitor-1 by placental growth factor in human pulmonary endothelial cells. Biochem J 434: 473-482
45. Rehmsmeier M, Steffen P, Hochsmann M, Giegerich R (2004) Fast and effective prediction of microRNA/target duplexes. RNA 10: 1507-1517 (Pubitemid 39288185)
46. Sachdeva M, Zhu S, Wu F, Wu H, Walia V, Kumar S, Elble R, Watabe K, Mo YY (2009) p53 represses c-Myc through induction of the tumor suppressor miR-145. Proc Natl Acad Sci USA 106: 3207-3212
47. Schepeler T, Reinert JT, Ostenfeld MS, Christensen LL, Silahtaroglu AN, Dyrskjot L, Wiuf C, Sorensen FJ, Kruhoffer M, Laurberg S, Kauppinen S, Orntoft TF, Andersen CL (2008) Diagnostic and prognostic microRNAs in stage II colon cancer. Cancer Res 68: 6416-6424
48. Sempere LF, Christensen M, Silahtaroglu A, Bak M, Heath CV, Schwartz G, Wells W, Kauppinen S, Cole CN (2007) Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer. Cancer Res 67: 11612-11620
49. Shetty S, Shetty P, Idell S, Velusamy T, Bhandary YP, Shetty RS (2008) Regulation of plasminogen activator inhibitor-1 expression by tumor suppressor protein p53. J Biol Chem 283: 19570-19580
50. Spizzo R, Nicoloso MS, Lupini L, Lu Y, Fogarty J, Rossi S, Zagatti B, Fabbri M, Veronese A, Liu X, Davuluri R, Croce CM, Mills G, Negrini M, Calin GA (2010) miR-145 participates with TP53 in a death-promoting regulatory loop and targets estrogen receptor-alpha in human breast cancer cells. Cell Death Differ 17: 246-254
51. Suzuki HI, Yamagata K, Sugimoto K, Iwamoto T, Kato S, Miyazono K (2009) Modulation of microRNA processing by p53. Nature 460: 529-533
52. Thorsen K, Sorensen KD, Brems-Eskildsen AS, Modin C, Gaustadnes M, Hein AM, Kruhoffer M, Laurberg S, Borre M, Wang K, Brunak S, Krainer AR, Torring N, Dyrskjot L, Andersen CL, Orntoft TF (2008) Alternative splicing in colon, bladder, and prostate cancer identified by exon array analysis. Mol Cell Proteomics 7: 1214-1224 (Pubitemid 352038268)
53. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, Harris CC, Croce CM (2006) A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 103: 2257-2261 (Pubitemid 43271657)
54. Wang Y, Lee CG (2009) MicroRNA and cancer-focus on apoptosis. J Cell Mol Med 13: 12-23
55. Wiklund ED, Bramsen JB, Hulf T, Dyrskjot L, Ramanathan R, Hansen TB, Villadsen SB, Gao S, OstenfeldMS, Borre M, Peter ME, Orntoft TF, Kjems J, Clark SJ (2011) Coordinated epigenetic repression of the miR-200 family and miR-205 in invasive bladder cancer. Int J Cancer 128: 1327-1334
56. Zaman MS, Chen Y, Deng G, Shahryari V, Suh SO, Saini S, Majid S, Liu J, Khatri G, Tanaka Y, Dahiya R (2010) The functional significance of microRNA-145 in prostate cancer. Br J Cancer 103: 256-264
57. Zhang H, Cai X, Wang Y, Tang H, Tong D, Ji F (2010a) microRNA-143, down-regulated in osteosarcoma, promotes apoptosis and suppresses tumorigenicity by targeting Bcl-2. Oncol Rep 24: 1363-1369
58. Zhang X, Wang X, Zhu H, Zhu C, Wang Y, Pu WT, Jegga AG, Fan GC (2010b) Synergistic effects of the GATA-4-mediated miR-144/451 cluster in protection against simulated ischemia/reperfusion-induced cardiomyocyte death. J Mol Cell Cardiol 49: 841-850